New pill aims to slow lung scarring in IPF patients
NCT ID NCT06747923
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called SB17170 in 30 adults with moderate to severe idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Participants take either the drug or a placebo daily for 12 weeks. The main goal is to see if the drug improves lung function, measured by how much air they can exhale.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SB17170 (an experimental oral drug)
What this could lead to
If successful, this could point toward a new treatment option to slow lung function decline in people with idiopathic pulmonary fibrosis.
What could go wrong
This is an early Phase 2a trial with only 30 participants, so results may not apply broadly. The drug may not improve lung function or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ajou University Hospital
NOT_YET_RECRUITINGSuwon, South Korea
Contact
-
Chung-Ang University Gwangmyeong Hospital
RECRUITINGGwangmyeong, South Korea
Contact
-
Myong Ji Hospital
RECRUITINGGoyang, South Korea
Contact
-
Seoul Asan Hospital
NOT_YET_RECRUITINGSeoul, South Korea
Contact
-
The Catholic Univ. of Korea Seoul St. Mary's Hospital
NOT_YET_RECRUITINGSeoul, South Korea
Contact